Development of preclinical system based on pulmonary functional imaging by hyperpolarized Xe MRI
Project/Area Number |
24300163
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Partial Multi-year Fund |
Section | 一般 |
Research Field |
Biomedical engineering/Biological material science
|
Research Institution | Osaka University |
Principal Investigator |
Kimura Atsuomi 大阪大学, 医学(系)研究科(研究院), 准教授 (70303972)
|
Co-Investigator(Renkei-kenkyūsha) |
TAKEDA Yoshito 大阪大学, 大学院医学系研究科, 助教 (40452388)
FUJIWARA Hideaki 大阪大学, 名誉教授 (90107102)
IMAI Hirohiko 京都大学, 大学院情報学研究科, 助教 (40506466)
|
Project Period (FY) |
2012-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥18,460,000 (Direct Cost: ¥14,200,000、Indirect Cost: ¥4,260,000)
Fiscal Year 2014: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥9,880,000 (Direct Cost: ¥7,600,000、Indirect Cost: ¥2,280,000)
|
Keywords | 超偏極キセノン / MRI / 肺機能診断 / 前臨床評価 / 新薬探索 / 難治性肺疾患 / イメージング / 慢性閉塞性肺疾患 / 前臨床評価系 / 超偏極 / 超偏極希ガス / 生体磁気共鳴計測 / MRS / 病態モデル |
Outline of Final Research Achievements |
A hyperpolarized Xe (HPXe) MRI system with extra-ordinary sensitivity was successfully developed by the use of original hyperpolarization techniques, enabling non-invasive pulmonary functional imaging unattainable by conventional methods and its application to preclinical evaluation. Treatment responses of a novel anti-inflammatory drug, ethyl pyruvate(EP), was confirmed exploring novel drugs for chronic obstructive pulmonary disease (COPD), fibrosis, and emphysema by the system. Especially, EP had reversely treated the alveolar tissue damages induced by fibrosis. To the best of the author's knowledge, this is a first report about preclinical evaluation strategy using HPXe MRI.
|
Report
(5 results)
Research Products
(19 results)